Holen Sie sich die Stockscreener-App
8.54
0.12%
-0.01
Handel nachbörslich:
8.54
Schlusskurs vom Vortag:
$8.55
Offen:
$8.55
24-Stunden-Volumen:
755.34K
Relative Volume:
0.20
Marktkapitalisierung:
$354.50M
Einnahmen:
$324.00K
Nettoeinkommen (Verlust:
$-82.10M
KGV:
-9.1828
EPS:
-0.93
Netto-Cashflow:
$-69.18M
1W Leistung:
+0.00%
1M Leistung:
+0.00%
6M Leistung:
+80.17%
1J Leistung:
+769.12%
1-Tages-Spanne:
$8.54
$8.55
1-Wochen-Bereich:
$8.54
$8.55
52-Wochen-Spanne:
$0.80
$8.55
Chimerix Inc Stock (CMRX) Company Profile
Firmenname
Chimerix Inc
Sektor
Branche
Telefon
919.806.1074
Adresse
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
Vergleichen Sie CMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMRX
Chimerix Inc
|
8.54 | 354.50M | 324.00K | -82.10M | -69.18M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Chimerix Inc Stock (CMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-05-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-09-07 | Eingeleitet | CapitalOne | Overweight |
| 2021-04-29 | Eingeleitet | Maxim Group | Buy |
| 2021-04-23 | Fortgesetzt | Cowen | Outperform |
| 2021-03-31 | Eingeleitet | Jefferies | Buy |
| 2021-03-31 | Eingeleitet | Wedbush | Outperform |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-02-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-09 | Bestätigt | FBR Capital | Mkt Perform |
| 2016-02-23 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2016-02-23 | Bestätigt | FBR Capital | Mkt Perform |
| 2016-02-23 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2016-02-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2015-12-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-12-28 | Herabstufung | FBR Capital | Outperform → Mkt Perform |
| 2015-12-28 | Bestätigt | Piper Jaffray | Overweight |
| 2015-12-17 | Eingeleitet | UBS | Buy |
| 2015-10-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2015-09-03 | Eingeleitet | Citigroup | Buy |
| 2015-08-18 | Eingeleitet | FBR Capital | Outperform |
| 2015-08-06 | Bestätigt | Brean Capital | Buy |
| 2015-05-11 | Bestätigt | Brean Capital | Buy |
| 2015-03-04 | Eingeleitet | Barclays | Overweight |
| 2015-02-12 | Bestätigt | Stifel | Buy |
| 2014-12-31 | Bestätigt | Brean Capital | Buy |
| 2014-07-08 | Fortgesetzt | Brean Capital | Buy |
Alle ansehen
Chimerix Inc Aktie (CMRX) Neueste Nachrichten
Former Chimerix CEO Andriole to lead Artios - biocentury.com
Jazz gets FDA okay for Chimerix brain cancer drug - pharmaphorum
Jazz Earnings: Xywav and Epidiolex Drive Growth; US Approval for Chimerix's Dordaviprone Promising - Morningstar
Chimerix buyout a win for Jazz with FDA nod for rare glioma drug - BioWorld MedTech
FDA approves targeted brain cancer drug from Jazz’s Chimerix buyout - Endpoints News
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut - TradingView
Jazz Pharmaceuticals 2025 Q2 Earnings Misses Targets as Net Loss Surges 538% - AInvest
Chimerix’s ONC201 Study: A Potential Game-Changer in Glioma Treatment - TipRanks
Comparing BetterLife Pharma (OTCMKTS:PVOTF) & Chimerix (NASDAQ:CMRX) - Defense World
Chimerix, Inc. (NASDAQ:CMRX) Shares Purchased by Two Sigma Investments LP - Defense World
Squarepoint Ops LLC Makes New Investment in Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Jane Street Group LLC Buys New Position in Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Two Sigma Advisers LP Has $41,000 Stock Holdings in Chimerix, Inc. (NASDAQ:CMRX) - Defense World
CHIMERIX Earnings Preview: Recent $CMRX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Northern Trust Corp Sells 36,038 Shares of Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Chimerix, Inc. (NASDAQ:CMRX) Shares Purchased by Millennium Management LLC - Defense World
Balyasny Asset Management L.P. Purchases Shares of 60,317 Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Chimerix (NASDAQ:CMRX) Now Covered by StockNews.com - Defense World
StockNews.com Initiates Coverage on Chimerix (NASDAQ:CMRX) - Defense World
Halper Sadeh LLP, bluebird bio, Inc., Walgreens Boots Alliance, Chimerix, Inc. - Olean Times Herald
Chimerix (NASDAQ:CMRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
Chimerix, Inc. to Host Earnings Call - ACCESS Newswire
Why Chimerix Inc. (CMRX) is Surging in 2025 - Insider Monkey
Investor Network: Chimerix, Inc. to Host Earnings Call - ACCESS Newswire
Geode Capital Management LLC Lowers Stock Holdings in Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Jazz Pharmaceuticals Acquires Chimerix for $935M - Contract Pharma
Jazz Pharmaceuticals Completes $935 Million Acquisition of Chimerix - marketscreener.com
Jazz Pharmaceuticals acquires Chimerix for $935 million By Investing.com - Investing.com South Africa
Chimerix Terminates Loan and Delists from Nasdaq - TipRanks
Jazz Pharmaceuticals Completes Acquisition of Chimerix | JAZZ St - GuruFocus
Jazz Pharmaceuticals (JAZZ) Completes Acquisition of Chimerix - StreetInsider
Jazz Pharmaceuticals Completes Acquisition of Chimerix - TipRanks
Jazz Pharmaceuticals acquires Chimerix for $935 million - Investing.com
Jazz Pharmaceuticals Completes Acquisition of Chimerix | JAZZ Stock News - GuruFocus
Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan
Jazz Pharmaceuticals' $935M Chimerix Deal: A Bold Move in Rare Oncology - AInvest
Chimerix stock soars to 52-week high, hits $8.54 By Investing.com - Investing.com South Africa
Chimerix stock soars to 52-week high, hits $8.54 - Investing.com
Unlocking Investment Potential Discover the Power of Magical Signals Bullish Signal - AInvest
Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
Chimerix stock soars to 52-week high, hits $8.53 By Investing.com - Investing.com Australia
Chimerix stock soars to 52-week high, hits $8.53 - Investing.com
Is Chimerix Inc. (CMRX) the Best Performing NASDAQ Stock So Far in 2025? - MSN
Jazz Pharmaceuticals, Chimerix HSR waiting period expired on March 31 - MLex
11 Best Performing NASDAQ Stocks So Far in 2025 - Insider Monkey
Exploring US High Growth Tech Stocks In March 2025 - simplywall.st
Finanzdaten der Chimerix Inc-Aktie (CMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
8.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):